OECD TG 471
OECD TG 471, OECD Test Guidelines for the Testing of Chemicals, Section 4 (Health Effects) in the context of the ‘Bacterial Reverse Mutation Test’, i.e. the bacterial reverse mutation test; this is commonly known as the Ames test. It was first adopted in 1983 and updated in 1997. The test is an in vitro genotoxicity test designed to assess a substance’s potential to induce reverse mutations in bacteria.
The basic principle of the test is as follows:
- The test uses auxotrophic bacterial mutant strains that are unable to synthesise a specific amino acid (e.g. histidine or tryptophan). These strains cannot grow on a minimal nutrient medium lacking these amino acids.
- The test substance is applied to these strains. If the test substance causes a back mutation, the bacteria are once again able to synthesise the amino acid and multiply by forming colonies on the minimal medium.
- Ein Anstieg der Rückmutationsrate ist ein Indikator für das mutagene Potenzial der Testsubstanz.
- The test is carried out both in the presence and in the absence of metabolic activation (S9 mixture). The S9 fraction (typically rat liver induced with phenobarbital and β-naphthoflavone) mimics mammalian metabolism and thus enables the detection of substances (promutagens) which, underin vivo conditions are converted into metabolites and thereby exert a mutagenic effect.
Commonly used test strains include:
- Salmonella typhimurium: TA98, TA100, TA1535, TA1537 (or TA97a/TA97), TA102 – each strain is sensitive to a different type of mutation (frameshift, base pair substitution, oxidative damage, etc.).
- Escherichia coli: WP2 uvrA (or WP2 uvrA pKM101) – is used in particular for base pair exchanges and oxidative damage.
- It is recommended that at least five strains (four S. typhimurium + one E. coli) be used; further strains may be added if necessary.
Test methods:
- Disc incorporation method (Petri dish incorporation): The test substance is poured into a Petri dish together with the bacteria and the cover layer of agar. This is a common and standardised procedure.
- Pre-incubation procedure: The test substance and the bacteria are subjected to a short pre-incubation (usually 20–30 minutes) in the presence of S9 and then poured into a Petri dish together with the cover layer agar. This method is particularly favoured for volatile substances and short-lived metabolites.
- If necessary, desiccators or gas-permeable systems can be used for volatile substances.
The key parameters reported in the study are as follows:
- The strains used and their genetic characteristics (type of mutation, R factor, uvrA/uvrB status, rfa wall mutation)
- Method used (plate incorporation or pre-incubation)
- Concentrations tested (usually at least 5 concentrations)
- Status of S9 metabolic activation (+S9 / −S9) and S9 concentration
- For each strain and each concentration, the number of revertant colonies (revertants per plate)
- Results of the negative (solvent) control and the positive control
- Dose-response relationship and statistical analysis
- Cytotoxicity of the test substance (reduction in the background lawn, shrinkage of colonies, etc.)
- Result: Assessment as mutagenic / non-mutagenic and justification
- Data on measurement uncertainty and repeatability
Why is the test carried out?
OECD Test Guideline 471 is carried out for the following scientific and regulatory purposes:
- Determination of mutagenic potential: assessment of the test substance’s potential to cause reverse mutations in bacterial DNA
- Assessment of genotoxic risk: early detection of substances that cause DNA damage; provision of a screening test in relation to carcinogenic potential
- Provision of preliminary data for in vivo testing: establishing a basis for following up positive in vitro results with in vivo genotoxicity tests (e.g. TG 474, TG 475)
- Detection of promutagens: identification of substances that are activated by the S9 metabolising system in the metabolism of mammals
- Support with authorisation applications: for use in safety assessments under REACH, as well as for biocides, plant protection products, medicinal products, cosmetics and food additives
- Core component of the genotoxicity test battery: inclusion as an initial test in regulatory genotoxicity testing strategies
- Approach to assessing the weight of evidence: a contribution to the holistic evaluation of the substance in conjunction with other genotoxicity tests, physicochemical data and exposure assessment
- Prioritisation: Screening a large number of substances and prioritising them for further testing
OECD TG 471 does not provide clear evidence of carcinogenicity or genotoxicity in mammals per se. Bacterial test systems differ from mammalian cells (metabolism, DNA repair, chromosome structure). The results should be interpreted in conjunction with other in vitro and in vivo genotoxicity tests, as well as an exposure assessment.
As part of our nano-testing services, we carry out bacterial back-mutation tests in accordance with OECD TG 471, utilising our accredited laboratory facilities and quality management system, and applying scientific rigour. Our scope of services includes the following:
Experimental design and preparation of the protocol
- Preparation of a study protocol in accordance with OECD TG 471
- Selection of the appropriate method (plate incorporation or pre-incubation) based on the physicochemical properties of the test substance (solubility, volatility, stability)
- Selection of a suitable solvent (vehicle) and assessment of solubility/stability
- Scientific justification for the concentration range and dosage levels
- Selection of strains and verification of their genetic characteristics
- Planning a negative control (solvent) and suitable positive controls
- Compliance with ethical and administrative requirements (including microbiological safety)
For information on study design, strain and method selection, planning of S9 metabolic activation, sample receipt conditions, testing schedule and reporting procedures for your bacterial back-mutation tests in accordance with OECD TG 471, please feel free to contact Nano-Test.

